Heidelberg Pharma AG’s Post

Congratulation to the collaborative teams led by Prof. Byeong-Seon Jeong, Prof. Jung-Ae Kim and Prof. Jun-Goo Jee for their recent research investigating a promising compound that may lead to new therapeutic approaches for hepatocellular carcinoma. The team designed and synthesized a series of novel hybrid compounds of sorafenib and 2,4,5-trimethylpyridine-3-ols, and they identified the best candidate, compound 6, for targeting hepatocellular carcinoma. Through various experiments, they demonstrated that compound 6 exhibited similar inhibitory efficacy to sorafenib but with fewer side effects. In this study, spheroid-forming ability of Huh7 and Hep3B cells by hybrid compounds and sorafenib was monitored and captured using our automated live-cell imaging system, Celloger® Mini (4 objective magnification). We appreciate that Celloger® was a part of the research. To read the full article: https://lnkd.in/gPNPsMBD More information about Celloger®: https://lnkd.in/d5zmFaat #livecellimaging #celloger #cellogermini #curiosis #spheroid #sorafenib #compound #hepatocellular #carcinoma

Curiosis Celloger Mini is revolutionizing live cell imaging systems, allowing scientists to monitor cell cultures in real time, inside the incubator, without disrupting the optimal environment for cell growth. With advanced microscopy, autofocusing, and multi-positioning technologies, Celloger systems capture high-quality images and videos of various cell types, including spheroids, stem cells, cancer cells, and neurons. So, why should researchers be excited about Celloger Mini? 1️⃣ More reliable and reproducible data: Celloger systems reduce variability and errors caused by manual handling, environmental changes, and human bias, ensuring more accurate results. 2️⃣ More comprehensive and insightful results: By capturing dynamic changes of cells over time, Celloger systems provide quantitative and qualitative data that enhance our understanding of cell behavior, function, and response to stimuli. 3️⃣ More innovative and impactful discoveries: Celloger systems enable new applications and experiments that were previously impossible with conventional methods, such as long-term observation, multi-point imaging, and image stitching. Curiosis Celloger is empowering researchers to elevate the quality of their scientific papers, paving the way for groundbreaking discoveries. Learn more about Celloger here: https://lnkd.in/edhwXCdR #ScientificResearch #LiveCellImaging #CuttingEdgeTechnology #Innovation

👀🎬 A look back on the first edition of #THRPTX. Few days ago, we hosted the inaugural Therapeutics Innovation Summit (THRPTX) at our R&D Institute at Paris-Saclay. This groundbreaking event brought together world-renowned scientists, researchers, and industry leaders to explore the frontiers of medical innovation, with a focus on oncology. 🔎 From AI-driven drug discovery to cutting-edge immunotherapies, the discussions illuminated pathways to transform patient care. Prof. William G. Kaelin, 2019 Nobel Laureate in Medicine, set the tone with his inspiring keynote on cellular adaptation to oxygen availability. 👉 The summit exemplified our commitment to open innovation and collaborative research. By fostering dialogue between diverse stakeholders, we aim to accelerate therapeutic progress and address unmet medical needs. 🙏 We're immensely grateful to all participants for their invaluable contributions. The insights gained will fuel our ongoing efforts to develop innovative solutions for patients facing cancer. Read more 👉 https://swll.to/xDshrVA #WeAreServier #MovedByYou #innovation #health

At this year’s ESMO Immuno-Oncology Congress, we shared additional data from our Phase 1 clinical trial for XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, including more patients treated at our recommended Phase 2 dose of 150 mg Q6W. The data showed XTX101 continues to demonstrate limited treatment-related adverse events and additional evidence of monotherapy anti-tumor activity in late-line and IO refractory patients across a range of tumor types. ➡ Check out our poster to learn more: https://lnkd.in/g4ekxA48 #xiliotx #cancerresearch #immunooncology #ESMOImmuno23

Deciphering the immunopeptidome of melanoma-derived EVs: in their latest work, Simon Powis and collaborators at the University of St Andrews characterised the HLA-I immunopeptidome of extracellular vesicles from melanoma cell line and from patients with advanced melanoma using HLA-I immunoisolation and mass spectrometry https://lnkd.in/e8m-i-9t The study suggested that the HLA-I immunopeptidome of blood-derived EVs may offer diagnostic or prognostic biomarkers and novel immunotherapy targets. An article also authored by Caitlin Boyne, Abbie Coote, Silvia Synowsky, Aaron Naden and Sally Shirran #extracellularvesicles #exosomes #massspectrometry #melanoma #Vesiculab

Check our latest article ''Why a multi-faceted oncology toolkit is essential for precision medicine'' in collaboration with Jérôme Sallette, our Chief Scientific Officer. In the article we dive deep into the key elements of a successful precision medicine strategy, including the interplay of innovative, customizable testing capabilities, from flow cytometry to genomics and spatial omics. A must-read if you want to achieve more predictive biomarker assessment and shorten the timeline to better oncology trials and therapies. Read more here: https://lnkd.in/eqz__kgj #TransformingResearch #AdvancingHealth #ClinicalResearch #PrecisionMedicine

Since their discovery, considerable efforts have been made to optimise #EGFR mutation detection approaches and the clinical management of EGFR-mutated #NSCLC.   📌 This review provides a comprehensive and up-to-date overview of the different detection platforms and therapeutic options currently available for the clinical management of advanced EGFR-positive NSCLC, summarising the scientific evidence and describing #moleculartesting and #therapeuticpractice in the real-world scenario.     👉 Get more information by reading this content published on the Official Journal of European School of Oncology and International Society of Liquid Biopsy. 🔗 https://lnkd.in/dM5b-K65 Umberto Malapelle | Sara Pilotto | Francesco Pepe | Pasquale Pisapia | Luisella Righi | Angela Listì | Paolo Bironzo | Lorenzo Belluomini | Fabrizio T. | Maria Lucia Reale | Gianluca Russo | Silvia Novello | Giancarlo Troncone

Our team is attending Biomarkers Europe 2023 in Berlin, Germany today and tomorrow! If you’re in attendance, feel free to reach out to us and listen to Kedar Hastak, PhD, Associate Director of Field Applications Scientists at Personalis, as he discusses NeXT Personal®, an ultra-sensitive ctDNA assay for accurate classification of patient MRD status and treatment monitoring. NeXT Personal, with 1-3 PPM MRD LOD, aids in the detection of MRD and recurrence at potentially earlier time points. Detections down to low PPM levels correlate strongly with poor overall and relapse-free survival, underscoring the need for ultra-sensitive approaches in diverse tumour indications, such as lung, melanoma, and gastric, amongst others. Learn more: https://bit.ly/3sDnkeb. #Biomarkers #BiomarkersSeries23 #PrecisionOncology #LiquidBiopsy

Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers

Read the latest Oncotarget #announcements and #pressreleases: https://lnkd.in/dd39jgy #openaccess #peerreviewed #oncology #cancer #researchpapers